All the participants also continued taking their normal nose spray during the study.
This nose spray contained a steroid called mometasone furoate. The dose of
mometasone furoate nasal spray was measured in micrograms, also called mcg.
The chart below shows the number of participants in the study and what
treatments they were given.
Benralizumab Placebo
• 207 participants • 206 participants
• 30 mg of benralizumab as an injection • Placebo as an injection
• 400 mcg of mometasone furoate • 400 mcg of mometasone furoate
nose spray nose spray
• benralizumab or placebo: 3 doses once every 4 weeks, then
5 doses once every 8 weeks, for a total of 56 weeks
• mometasone furoate: 2 sprays in each nostril twice a day,
for the entire study
What happened during this study?
Half of the participants were in the study for up to 65 weeks. The other half of
the participants had additional visits to the study site after they stopped taking
the study treatment. These participants were in the study for up to 85 weeks. The
entire study took 2.5 years to finish.
The study started in January 2018 and ended in July 2020.
For the participants who were still in the study when the COVID-19 pandemic
started:
X Some of their site visits may have been delayed or canceled.
X Some of the tests that had been planned were not done.
X Some site visits may have been replaced with phone calls.
X They may have completed some questionnaires remotely.
6 | Clinical Study Results